Trials / Unknown
UnknownNCT05478343
Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a open-label to determine the efficacy and safety of IM21 CAR-T cells in adult with R/R multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IM21 CAR-T cells | IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range. |
Timeline
- Start date
- 2021-05-06
- Primary completion
- 2023-05-01
- Completion
- 2023-08-01
- First posted
- 2022-07-28
- Last updated
- 2022-07-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05478343. Inclusion in this directory is not an endorsement.